Mark Hatherill

List of Publications by Year
in descending order

121 papers	8,717 citations	71102 41 h-index	48315 88 g-index
126 all docs	126 docs citations	126 times ranked	6885 citing authors

#	Article	IF	Citations
1	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, The, 2013, 381, 1021-1028.	13.7	903
2	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, The, 2016, 387, 2312-2322.	13.7	678
3	Prevention of *M. tuberculosis* Infection with H4:IC31 Vaccine or BCG Revaccination. New England Journal of Medicine, 2018, 379, 138-149.	27.0	532
4	Specific T Cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis after Bacillus Calmette-Guérin Vaccination of Newborns. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1073-1079.	5.6	386
5	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. New England Journal of Medicine, 2014, 371, 1599-1608.	27.0	383
6	Final Analysis of a Trial of M72/AS01$_E$ Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 2019, 381, 2429-2439.	27.0	350
7	Phase 2b Controlled Trial of M72/AS01$_E$ Vaccine to Prevent Tuberculosis. New England Journal of Medicine, 2018, 379, 1621-1634.	27.0	319
8	T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications, 2016, 7, 11290.	12.8	236
9	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1198-1208.	5.6	217
10	The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4$^+$ and CD8$^+$ T Cells in Adults. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1407-1417.	5.6	211
11	Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathogens, 2017, 13, e1006687.	4.7	193
12	First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine, 2015, 33, 4130-4140.	3.8	183
13	Modified vaccinia Ankara–expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4$^+$ T cells. European Journal of Immunology, 2010, 40, 279-290.	2.9	171
14	Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host and Microbe, 2017, 21, 695-706.e5.	11.0	164
15	Tuberculosis Vaccines and Prevention of Infection. Microbiology and Molecular Biology Reviews, 2014, 78, 650-671.	6.6	133
16	A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy M. tuberculosis Infected South Africans. PLoS Pathogens, 2016, 12, e1005760.	4.7	128
17	Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of *Mycobacterium tuberculosis* Infection. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 638-648.	5.6	124
18	Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respiratory Medicine,the, 2018, 6, 287-298.	10.7	122

#	Article	IF	Citations
19	Bacillus Calmetteâ€"GuÃ©rin (BCG) Revaccination of Adults with Latent <i>Mycobacterium tuberculosis</i> Infection Induces Long-Lived BCG-Reactive NK Cell Responses. Journal of Immunology, 2016, 197, 1100-1110.	0.8	121
20	The Tuberculin Skin Test versus QuantiFERON TB GoldÂ® in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa. PLoS ONE, 2011, 6, e17984.	2.5	119
21	Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine, 2015, 33, 4025-4034.	3.8	110
22	Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 282-290.	10.7	110
23	The Dynamics of QuantiFERON-TB Gold In-Tube Conversion and Reversion in a Cohort of South African Adolescents. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 584-591.	5.6	108
24	Progress and challenges in TB vaccine development. F1000Research, 2018, 7, 199.	1.6	93
25	Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respiratory Medicine,the, 2019, 7, 757-770.	10.7	92
26	Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ: British Medical Journal, 2008, 337, a2052-a2052.	2.3	90
27	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, 2020, 10, 8629.	3.3	90
28	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 354-365.	9.1	84
29	The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses. PLoS ONE, 2014, 9, e87340.	2.5	79
30	A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathogens, 2019, 15, e1007643.	4.7	79
31	A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or <i>Mycobacterium tuberculosis</i>â€"infected Adults. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 769-778.	5.6	78
32	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 220-231.	5.6	75
33	Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. PLoS Medicine, 2019, 16, e1002781.	8.4	72
34	The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine, 2015, 33, 3592-3599.	3.8	71
35	T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. European Respiratory Journal, 2018, 51, 1800153.	6.7	65
36	Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa. Bulletin of the World Health Organization, 2010, 88, 312-320.	3.3	62

#	ARTICLE	IF	CITATIONS
37	Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Frontiers in Microbiology, 2019, 10, 3154.	3.5	56
38	Human newborn bacille Calmetteâ€"GuÃ©rin vaccination and risk of tuberculosis disease: a case-control study. BMC Medicine, 2016, 14, 76.	5.5	55
39	MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. Journal of Immunology, 2019, 203, 2917-2927.	0.8	55
40	Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies. Lancet Respiratory Medicine,the, 2019, 7, 544-552.	10.7	52
41	Noninvasive Detection of Tuberculosis by Oral Swab Analysis. Journal of Clinical Microbiology, 2019, 57, .	3.9	50
42	Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells. Tuberculosis, 2018, 108, 124-126.	1.9	49
43	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 1441.	3.5	46
44	Safety and immunogenicity of the adjunct therapeutic vaccine ID93â€+â€˜GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respiratory Medicine,the, 2021, 9, 373-386.	10.7	46
45	Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results. Clinical Infectious Diseases, 2022, 74, 2136-2141.	5.8	46
46	Functional, Antigen-Specific Stem Cell Memory (TSCM) CD4+ T Cells Are Induced by Human Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 324.	4.8	44
47	Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. JCI Insight, 2019, 4, .	5.0	42
48	The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine, 2014, 32, 5908-5917.	3.8	41
49	Differential Recognition of <i>Mycobacterium tuberculosis</i>â€"Specific Epitopes as a Function of Tuberculosis Disease History. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 772-781.	5.6	39
50	Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0237574.	2.5	39
51	A Functional Toll-Interacting Protein Variant Is Associated with Bacillus Calmette-GuÃ©rinâ€"Specific Immune Responses and Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 502-511.	5.6	38
52	Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis, 2013, 93, 143-149.	1.9	35
53	Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. Lancet Infectious Diseases, The, 2019, 19, e65-e76.	9.1	35
54	H1:IC31 vaccination is safe and induces long-lived TNF-Î±+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial. Vaccine, 2017, 35, 132-141.	3.8	34

#	Article	IF	Citations
55	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. The Lancet Global Health, 2021, 9, e841-e853.	6.3	34
56	Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine, 2014, 32, 3982-3988.	3.8	33
57	Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Clinical Infectious Diseases, 2018, 66, 554-563.	5.8	32
58	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis, 2018, 109, 61-68.	1.9	28
59	Isolation of Non-Tuberculous Mycobacteria in Children Investigated for Pulmonary Tuberculosis. PLoS ONE, 2006, 1, e21.	2.5	28
60	Accelerating research and development of new vaccines against tuberculosis: a global roadmap. Lancet Infectious Diseases, The, 2022, 22, e108-e120.	9.1	28
61	Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1556-1565.	5.6	25
62	Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. BMC Infectious Diseases, 2014, 14, 314.	2.9	24
63	Clinical Testing of Tuberculosis Vaccine Candidates. Microbiology Spectrum, 2016, 4, .	3.0	24
64	18F-FDG PET/CT as a Noninvasive Biomarker for Assessing Adequacy of Treatment and Predicting Relapse in Patients Treated for Pulmonary Tuberculosis. Journal of Nuclear Medicine, 2020, 61, 412-417.	5.0	23
65	Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Research, 2017, 1, 9.	1.1	22
66	Screening for TB in high school adolescents in a high burden setting in South Africa. Tuberculosis, 2013, 93, 357-362.	1.9	21
67	Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials. Clinical Infectious Diseases, 2012, 54, 493-501.	5.8	19
68	Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed Controls. Journal of Infectious Diseases, 2020, 222, 995-1007.	4.0	19
69	Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial. PLoS ONE, 2015, 10, e0141623.	2.5	19
70	Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. EBioMedicine, 2022, 76, 103839.	6.1	19
71	Safety and Immunogenicity of Early Bacillus Calmette-Guérin Vaccination in Infants Who Are Preterm and/or Have Low Birth Weights. JAMA Pediatrics, 2019, 173, 75.	6.2	18
72	Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or *Mycobacteriu* *m tuberculosis* Infection. Clinical Infectious Diseases, 2021, 73, e3398-e3408.	5.8	18

#	ARTICLE	IF	CITATIONS
73	The lactate:pyruvate ratio following open cardiac surgery in children. Intensive Care Medicine, 2007, 33, 822-829.	8.2	17
74	Prospects for elimination of childhood tuberculosis: the role of new vaccines. Archives of Disease in Childhood, 2011, 96, 851-856.	1.9	17
75	A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe. Vaccine, 2015, 33, 4719-4726.	3.8	17
76	Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection. EBioMedicine, 2021, 64, 103233.	6.1	17
77	The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes. Tuberculosis, 2017, 104, 38-45.	1.9	16
78	Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 1529.	4.8	16
79	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
80	Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1463-1472.	5.6	15
81	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Communications Medicine, 2022, 2, .	4.2	15
82	Phenotypic variability in childhood TB: Implications for diagnostic endpoints in tuberculosis vaccine trials. Vaccine, 2011, 29, 4316-4321.	3.8	14
83	Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population. PLoS ONE, 2017, 12, e0184563.	2.5	14
84	Postnatal Expansion, Maturation, and Functionality of MR1T Cells in Humans. Frontiers in Immunology, 2020, 11, 556695.	4.8	14
85	Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines. Communications Biology, 2020, 3, 563.	4.4	14
86	Sample adequacy controls for infectious disease diagnosis by oral swabbing. PLoS ONE, 2020, 15, e0241542.	2.5	14
87	BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. Clinical Infectious Diseases, 2016, 62, S262-S267.	5.8	13
88	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Scientific Reports, 2019, 9, 11126.	3.3	13
89	Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-γ in QuantiFERON assays in healthy persons. Tuberculosis, 2015, 95, 350-351.	1.9	12
90	Predicting tuberculosis risk – Authors' reply. Lancet, The, 2016, 388, 2233-2234.	13.7	12

#	Article	IF	Citations
91	Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria. PLoS ONE, 2018, 13, e0208940.	2.5	12
92	Diagnostic Accuracy of Early Secretory Antigenic Target-6â€"Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube. Clinical Infectious Diseases, 2019, 69, 1724-1730.	5.8	12
93	Immune serumâ€"activated human macrophages coordinate with eosinophils to immobilize *Ascaris suum* larvae. Parasite Immunology, 2020, 42, e12728.	1.5	11
94	Plasma Type I IFN Protein Concentrations in Human Tuberculosis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 296.	3.9	10
95	Molecular Detection of Airborne *Mycobacterium tuberculosis* in South African High Schools. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 350-356.	5.6	10
96	Comparison of Mantoux and Tine Tuberculin Skin Tests in BCG-Vaccinated Children Investigated for Tuberculosis. PLoS ONE, 2009, 4, e8085.	2.5	9
97	Mycobacterium tuberculosis-Specific T Cell Functional, Memory, and Activation Profiles in QuantiFERON-Reverters Are Consistent With Controlled Infection. Frontiers in Immunology, 2021, 12, 712480.	4.8	8
98	Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol. BMJ Open, 2019, 9, e026612.	1.9	7
99	Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies. PLoS Medicine, 2019, 16, e1002795.	8.4	7
100	Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young Adults. Frontiers in Immunology, 2021, 12, 639965.	4.8	7
101	Clinical predictors of pulmonary tuberculosis among South African adults with HIV. EClinicalMedicine, 2022, 45, 101328.	7.1	7
102	End-point definition and trial design to advance tuberculosis vaccine development. European Respiratory Review, 2022, 31, 220044.	7.1	7
103	Novel vaccine prime and selective BCG boost: A new tuberculosis vaccine strategy for infants of HIV-infected mothers. Vaccine, 2010, 28, 4550-4552.	3.8	6
104	Blood transcriptional signatures for tuberculosis testing. Lancet Respiratory Medicine,the, 2020, 8, 330-331.	10.7	6
105	REL and BHLHE40 Variants Are Associated with IL-12 and IL-10 Responses and Tuberculosis Risk. Journal of Immunology, 2022, 208, 1352-1361.	0.8	6
106	Regional changes in tuberculosis disease burden among adolescents inÂSouth AfricaÂ(2005â€"2015). PLoS ONE, 2020, 15, e0235206.	2.5	5
107	Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol. BMJ Open, 2021, 11, e048623.	1.9	5
108	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. BMC Medicine, 2021, 19, 252.	5.5	4

#	Article	IF	Citations
109	Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol. BMJ Open, 2017, 7, e014609.	1.9	3
110	Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. EClinicalMedicine, 2022, 47, 101396.	7.1	3
111	Non-volatile organic compounds in exhaled breath particles correspond to active tuberculosis. Scientific Reports, 2022, 12, 7919.	3.3	3
112	Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis. Frontiers in Medicine, 2022, 9, 791653.	2.6	2
113	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. EBioMedicine, 2022, 77, 103886.	6.1	2
114	Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition. PLoS ONE, 2022, 17, e0267729.	2.5	2
115	First-in-human trial of a live-attenuated Mycobacterium tuberculosis vaccine. Lancet Respiratory Medicine,the, 2015, 3, 906-907.	10.7	1
116	Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. International Journal of Epidemiology, 2016, 45, 580-580.	1.9	1
117	Clinical Testing of Tuberculosis Vaccine Candidates. , 2017, , 193-211.		1
118	Multidimensional analysis of immune responses identified biomarkers of recent Mycobacterium tuberculosis infection. PLoS Computational Biology, 2021, 17, e1009197.	3.2	1
119	The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study. Vaccine, 2022, 40, 364-369.	3.8	1
120	POLICY-DRIVEN INTERVENTIONS: TUBERCULOSIS. BMJ Global Health, 2017, 2, A4.1-A4.	4.7	0
121	120. A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01E Vaccine Against Pulmonary Tuberculosis Disease in Adults With Latent Mycobacterium tuberculosis Infection. Open Forum Infectious Diseases, 2018, 5, S5-S6.	0.9	0